CagriSema
Neutral, BioHarmony verdict
BioHarmony score 5.1 out of 10
CagriSema is an investigational once-weekly amylin plus GLP-1 injectable that produced about 22.7% weight loss on-treatment in REDEFINE 1, per Garvey 2025 in NEJM. It is not yet approved and lost a head-to-head to tirzepatide.
Read full reportWhat is CagriSema?
CagriSema is an investigational once-weekly injection that combines two appetite drugs in a single dual-chamber pen: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 drug already sold as Wegovy and Ozempic. The idea is simple. Stack two different fullness signals and you get more weight loss than either alone. In the big Phase 3 obesity trial, people without diabetes lost about 22.7% of their body weight on-treatment over 68 weeks, per Garvey 2025. That is the biggest effect size I have scored in this incretin batch.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Two appetite pathways at once: GLP-1 satiety plus amylin satiety and gastric slowing
Safety watch-outs
- Severe, persistent abdominal pain radiating to the back (possible pancreatitis): stop and seek care.
- A neck lump, hoarseness, or trouble swallowing (possible thyroid signal): stop and consult a clinician.
- Vomiting or diarrhea bad enough to cause dehydration: pause dosing and rehydrate, get medical help if it persists.
- Personal or family history of medullary thyroid carcinoma or MEN 2: do not use, the class carries a thyroid C-cell warning.
- Active gallbladder disease or signs of gallstones: consult a clinician before continuing.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for CagriSema yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (1)
Attributed viewpoints, separate from primary research.
- CagriSema Dosage Chart: How to Dose This Peptide Combo Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Novo Nordisk reports that CagriSema was submitted to FDA for weight management and remains under regulatory review.
Primary sources
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.